{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-045840","form_type":"8-K","ticker":"ENVB","cik":"0000890821","company_name":"Enveric Biosciences, Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.284534+00:00","generated_at":"2026-05-30T00:42:37.722163+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Enveric Biosciences Q3 net loss narrows to $2.1M; advances EB-003","bullets":["Net loss of $2.1M ($0.24/share) vs $2.8M ($1.30/share) a year ago; cash $3.1M.","Lead candidate EB-003 shows oral bioavailability and brain exposure; IND filing expected H2 2025.","Out-licensed radiation dermatitis product to Aries Science & Technology and EB-002 to MycoMedica.","Expanded patent estate with five new US patents for EVM301 portfolio."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-045840","json":"https://secwatch.observer/filing/0001493152-24-045840.json","markdown":"https://secwatch.observer/filing/0001493152-24-045840.md","text":"https://secwatch.observer/filing/0001493152-24-045840.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/890821/000149315224045840/0001493152-24-045840-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/890821/000149315224045840/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:42:37.722163+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}